

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

### Proposed Health Technology Appraisal

#### Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• GlaxoSmithKline (lapatinib)</li> <li>• Roche Products (trastuzumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Breakthrough Breast Cancer</li> <li>• Breast Cancer Campaign</li> <li>• Breast Cancer Care</li> <li>• Breast Cancer Haven</li> <li>• Breast Cancer UK</li> <li>• CANCERactive</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• National Cancer Alliance</li> <li>• National Council for Palliative Care</li> <li>• South Asian Health Foundation</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Commissioning Support Appraisals Unit</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association for Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis (tamoxifen)</li> <li>• Arrow Generics (tamoxifen)</li> <li>• AstraZeneca (anastrozole, tamoxifen)</li> <li>• Kent Pharmaceuticals (tamoxifen)</li> <li>• Mylan (tamoxifen)</li> <li>• Novartis Pharmaceuticals (letrozole)</li> <li>• Pfizer (exemestane, tamoxifen)</li> <li>• Rosemont Pharmaceuticals (tamoxifen)</li> <li>• Sandoz (tamoxifen)</li> <li>• Teva UK (tamoxifen)</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2

Issue date: November 2009

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder Care</li> <li>• Tenovus Cancer Information Centre</li> <li>• Women’s Health Concern</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Oncological Association</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians, Medical Oncology Joint Special Committee</li> <li>• Royal College of Radiologists</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Conwy LHB</li> <li>• Department of Health</li> <li>• Portsmouth City Teaching PCT</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• Wockhardt (tamoxifen)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Against Breast Cancer</li> <li>• Breast Cancer Hope</li> <li>• Breast Cancer Research Trust</li> <li>• Cochrane Collaboration – Cochrane Breast Cancer Group</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Pro-Cancer Research Fund</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Liverpool Reviews &amp; Implementation Group, University of Liverpool</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2

NICE is committed to promoting equality and eliminating unlawful discrimination.  
Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2

Issue date: November 2009

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2

Issue date: November 2009